THE MOMENT YOUR EXPERIMENT YIELDS AN INCREDIBLE RESULT.

THE DIFFERENCE OF BREAKING THROUGH BARRIERS WITH BRILLIANCE

ENABLING GREATER EXPERIMENTAL POWER WITH AN EXTENSIVE PORTFOLIO OF TRUSTED REAGENTS. Every day, researchers at the forefront of discovery trust reagents to power deeper cellular analysis. That's why we deliver innovative dyes to give you more resolution and flexibility in your experimental design. With one of the largest portfolios of high-quality reagents in the industry—backed by scientific publications and unparalleled support—our cutting-edge reagents will help take your research to the next level. Discover the new BD.

Learn how you can advance your research >
Differential Regulation of Human Bone Marrow Mesenchymal Stromal Cell Chondrogenesis by Hypoxia Inducible Factor-1α Hydroxylase Inhibitors

DHERAJ K. TAHEEM a, DANIEL A. FOYT a, SANDRA LOAIZA b, SILVIA A. FERREIRA a, DUSKO ILIC c, HOLGER W. AUNER b, AGAMEMNON E. GRIGORIADIS a, GAVIN JELL d, EILEEN GENTLEMAN a

Key Words. Bone marrow stromal cells (BMSCs) • Cell signaling • Chondrogenesis • Differentiation • Hypoxia • Mesenchymal stem cells (MSCs) • Tissue regeneration

ABSTRACT

The transcriptional profile induced by hypoxia plays important roles in the chondrogenic differentiation of marrow stromal/stem cells (MSC) and is mediated by the hypoxia inducible factor (HIF) complex. However, various compounds can also stabilize HIF’s oxygen-responsive element, HIF-1α, at normoxia and mimic many hypoxia-induced cellular responses. Such compounds may prove efficacious in cartilage tissue engineering, where microenvironmental cues may mediate functional tissue formation. Here, we investigated three HIF-stabilizing compounds, which each have distinct mechanisms of action, to understand how they differentially influenced the chondrogenesis of human bone marrow-derived MSC (hBM-MSC) in vitro. hBM-MSCs were chondrogenically-induced in transforming growth factor-β3-containing media in the presence of HIF-stabilizing compounds. HIF-1α stabilization was assessed by HIF-1α immunofluorescence staining, expression of HIF target and articular chondrocyte specific genes by quantitative polymerase chain reaction, and cartilage-like extracellular matrix production by immunofluorescence and histochemical staining. We demonstrate that all three compounds induced similar levels of HIF-1α nuclear localization. However, while the 2-oxoglutarate analog dimethyloxalylglycine (DMOG) promoted upregulation of a selection of HIF target genes, desferrioxamine (DFX) and cobalt chloride (CoCl2), compounds that chelate or compete with divalent iron (Fe2+), respectively, did not. Moreover, DMOG induced a more chondrogenic transcriptional profile, which was abolished by Acriflavine, an inhibitor of HIF-1α-HIF-β binding, while the chondrogenic effects of DFX and CoCl2 were more limited. Together, these data suggest that HIF-1α function during hBM-MSC chondrogenesis may be regulated by mechanisms with a greater dependence on 2-oxoglutarate than Fe2+ availability. These results may have important implications for understanding cartilage disease and developing targeted therapies for cartilage repair.

SIGNIFICANCE STATEMENT

The repair of damaged cartilage with engineered tissues may be hampered by challenges stemming from the need to provide appropriate environmental cues to progenitor cells. By chemically targeting the hypoxia inducible factor (HIF) complex to mimic the effects of hypoxia, it is shown that the 2-oxoglutarate (2-OG) analog dimethyloxalylglycine (DMOG) induces HIF signaling and a more articular chondrocyte-like expression profile in human bone marrow-derived mesenchymal stem cells (BM-MSC) compared with cobalt chloride or desferrioxamine, which reduce divalent iron (Fe2+2) bioavailability. These observations suggest that human BM-MSC may rely more on mechanisms that utilize 2-OG than Fe2+ during chondrogenesis and suggest that DMOG could be effective therapeutically for cartilage regeneration.

INTRODUCTION

Acute lesions to the articular cartilage that do not heal may be painful and can progress to osteoarthritis. Conventional treatments such as microfracture or articular chondrocyte implantation are not always effective in mediating repair [1, 2]. Tissue engineering strategies that combine cells with bioactive factors and biomaterial scaffolds may allow for de novo articular cartilage formation and provide an alternative therapy for patients [3–5]. However, the provision of cues that can appropriately direct progenitor cell differentiation and tissue formation remain a challenge.

One of the regulatory factors controlling articular cartilage development is the cellular...
response to physiological hypoxia [6, 7]. The cellular response to hypoxia is mediated by the hypoxia inducible factor [8] pathway which induces expression of hypoxia-responsive genes [9]. At normoxia, the hypoxia inducible factor (HIF) complex is unable to recruit the oxygen-responsive HIF-1α subunit, which inhibits expression of genes containing a HIF response element within their promoter regions [10]. Under hypoxic conditions, HIF-1α translocates to the nucleus where it complexes with other components of the HIF complex to initiate transcription of HIF target genes [10]. HIF-1α is central in the formation of articular cartilage during development [6, 7]. It also plays essential roles in the differentiation of mesenchymal stem/stromal cells (MSC) [11, 12] and chondroprogenitors [13] into cells capable of producing cartilage-like extracellular matrix (ECM) [14–16]. Moreover, HIF-1α is vital in maintaining the articular phenotype of differentiated chondrocytes and inhibiting hypertrophic differentiation [17].

Two hydroxylases, prolyl hydroxylase 2 (PHD2) and factor inhibiting HIF (FIH), regulate the participation of HIF-1α in the HIF complex [18, 19]. Each catalyzes the hydroxylation of specific residues on HIF-1α by utilizing molecular oxygen (O₂) as a substrate together with ascorbic acid, iron (Fe²⁺) and 2-oxoglutarate (2-OG). PHD2-mediated proline hydroxylation results in ubiquitination of HIF-1α and its subsequent proteasomal degradation, whereas asparagine hydroxylation by FIH prevents HIF-1α from binding to the co-factor, p300 in the HIF complex [18]. Under hypoxic conditions, the lack of oxygen reduces PHD2 and FIH activity, enabling HIF-1α to accumulate in the nucleus and form an active transcriptional complex with co-factors at the promoter regions of HIF target genes.

The importance of hypoxia and HIF in cartilage development and maintenance point toward its potential utility in cartilage tissue engineering strategies. Indeed, chemical agents that upregulate HIF have been shown to drive the chondrogenic differentiation of MSC and promote articular chondrocytes to produce a cartilage-like ECM [12, 20, 21]. However, studies which compare the efficacy of different HIF-stimulating compounds in driving the chondrogenesis of human bone marrow-derived mesenchymal stem cells (hBM-MSC) compared with standard protocols which utilize transforming growth factor-β (TGF-β), are lacking.

Therefore, we compared the effects of three hydroxylase inhibitors on the chondrogenic differentiation of hBM-MSC. Dimethyloxalylglycine (DMOG) strongly binds to the 2-OG binding pocket of both FIH and PHD2, acting as a competitive inhibitor [22]; desferrioxamine (DFX) sequesters intracellular Fe²⁺, which is required by FIH and PHD2 [23], and thereby reduces their activity; and cobalt chloride (CoCl₂) competes with Fe²⁺ by directly binding to the PHD2 active site [24]. We chose these agents because they cover the main classes of HIF-stimulating compounds, and as such, upregulate HIF-1α via distinct mechanisms (Fig. 1A, 1B). These compounds are also the most widely studied for chemically regulating HIF and may shed light on key regulatory elements of hypoxic signaling during chondrogenesis. Moreover, investigating the PHD2/ FIH inhibitors during hBM-MSC chondrogenesis may aid our understanding of the pathophysiology of degenerative diseases such as osteoarthritis [8], for which HIF-1α is known to play a protective role [25].

Here, we show that while CoCl₂, DFX, and DMOG all induce similar levels of HIF-1α stabilization, only DMOG strongly enhances HIF-mediated transcription of key chondrogenic genes. Nevertheless, DMOG negatively impacted the production of Collagen Type II and glycosaminoglycans (GAGs), which could be alleviated by only exposing cells to the compound during the latter stages of chondrogenesis. Together, these observations highlight the potential importance of mechanisms which utilize 2-OG compared with Fe²⁺ for the transcriptional control of HIF target genes during hBM-MSC chondrogenesis. They also suggest that 2-OG inhibitors may better promote a chondrogenic transcriptome compared with either DFX or CoCl₂. These observations may inform on improved, targeted strategies for stimulating cartilage ECM formation in tissue engineering-based therapies.

**MATERIALS AND METHODS**

**Isolation and Expansion of hBM-MSC**

hBM-MSCs were isolated from bone marrow aspirates collected from the iliac crest of healthy pediatric donors, with informed consent from their parents or guardians. Cells were seeded in CellSTACK (Corning, Sigma Aldrich, UK) culture chambers at 10–25 × 10³/636 cm² and cultured in αMEM supplemented with human platelet lysate (Stemulate, Cook Medical, USA). At 90%–100% confluency, cells were passaged and seeded at 5,000 cells per cm². For immunophenotyping of hBM-MSCs, the following antibodies were used in conjunction with a FACSCalibur analyzer (BD Biosciences, UK): CD90-FITC, CD105-APC, CD73-PE, CD34-PE, and CD45-FITC (all from BD Biosciences). All human tissue was approved for use by the UK National Research Ethics Service (12/WA/0196) and was collected by the National Institute for Health Research, which is supported by the Imperial College Healthcare Tissue Bank (HTA license 12275). Cultures were found to express CD90, CD105, CD73 and not express hematopoietic markers CD34 and CD45 [26] (data not shown). hBM-MSCs were expanded in growth media (GM; αMEM + 10% fetal bovine serum [FBS], Thermo Fisher Scientific, UK) under standard conditions (5% CO₂).

**Chondrogenic Induction of hBM-MSC**

hBM-MSCs were expanded to passage 5 in GM under standard culture conditions before cryopreservation in a solution composed of 10% dimethyl sulfoxide, Sigma-Aldrich, 40% FBS, and 50% GM. Cells were stored in liquid nitrogen prior to use. For chondrogenic induction experiments, cryovials of hBM-MSCs were thawed in GM and grown to confluence before plating at 3 × 10⁴/cm² into multi-well tissue culture plates. Cultures were incubated for 24 hours in GM prior to induction using standard chondrogenic differentiation media (CDM). See Figure 1C for experimental plan. Cells were differentiated as monolayers to prevent the formation of a local hypoxic microenvironment independent of experimental conditions (physiological or chemically induced hypoxia). Indeed, while pellet/micromass cultures may be more conducive for chondrogenesis, the bioavailability of oxygen may vary between cells at the periphery and center of such cultures. CDM consisted of High Glucose Dulbecco’s modified Eagle medium (Sigma-Aldrich) + 2 mM L-Glutamine (Thermo Fisher Scientific) + 100 nM Dexamethasone (Sigma-Aldrich) + 1% Insulin, Transferrin, Selenium Solution (Thermo Fisher Scientific) + 1% Antibiotic Antimycotic solution (Sigma-Aldrich) + 50 μg/ml Ascorbic acid-2-phosphate (Sigma-Aldrich) + 1% Bovine Serum Albumin (Thermo Fisher Scientific) + 1% Fetal Bovine Serum (Life Technologies).
Aldrich) + 40 μg/ml l-proline (Sigma Aldrich) + 10 ng/ml TGF-β3 (Peprotech). CDM was supplemented with HIF-stabilizing compounds (Sigma-Aldrich): 100 μM CoCl2, 50 μM DFX, and 200 μM DMOG, or incubated in un-supplemented CDM at hypoxia (5%O2) or normoxia. To achieve HIF-1α inhibition, media was further supplemented with 500 nM Acriflavine (ACF; Santa Cruz Biotechnology, USA).

Neutral Red Viability Assay
Neutral red dye (Sigma-Aldrich) dissolved in cell culture medium was incubated with differentiating hBM-MSC for 2 hours before fixation in 0.1% Calcium Chloride + 0.5% paraformaldehyde (both from Sigma-Aldrich). Dye retained by hBM-MSC was solubilized in 1% acetic acid + 50% ethanol (both from Sigma-Aldrich). Quantification of solubilized Neutral Red was then performed on an absorbance spectrophotometer at 540 nm.

PicoGreen Assay
Samples were snap-frozen at −80°C and digested in 400 μg/ml Papain Buffer at 65°C for 18 hours. Double stranded deoxyribonucleic acid (dsDNA) content in papain-digested cultures was quantified using a PicoGreen kit (Thermo Fisher Scientific).

Figure 1. Schematics highlighting the role of hydroxylase inhibitors in regulation of HIF-1α-mediated transcription and the study experimental design. (A): Under hypoxic conditions, HIF-1α forms an active transcription complex with HIF-1β and co-factors such as CBP/p300. This HIF complex then binds to the promoter regions of target genes at the HIF-response element sites, inducing transcription. (B): At normoxia, two hydroxylases—PHD2 and FIH, utilize oxygen and other substrates to hydroxylate HIF-1α which promotes its degradation and inhibits binding by CBP/p300. Here, we aimed to stabilize HIF-1α at normoxia by inhibiting the hydroxylases with CoCl2, DFX or DMOG. (C): Experiment design. To produce each biological replicate, hBM-MSCs were thawed and expanded to passage 5 before re-seeding at a density of 3 × 10^4 cell per cm^2 in multi-well plates. Each well or set of wells was assigned to a specific condition: 20%O2, 20%O2 + CoCl2, 20%O2 + DFX, 20%O2 + DMOG, or 5%O2. Separate experiments included each HIF-stabilizing compound in the presence or absence of ACF, and a comparison of late with constitutive exposure. In each condition, cultures were chondrogenically differentiated before assays at the time points specified in the legend of each figure. Abbreviations: ACF, Acriflavine; CoCl2, cobalt chloride; DFX, desferrioxamine; DMOG, dimethyloxalylglycine; ECM, extracellular matrix; FIH, factor inhibiting hypoxia inducible factor; hBM-MSCs, human bone marrow-derived mesenchymal stem cells; HIF, hypoxia inducible factor; PHD2, prolyl hydroxylase 2.
detected on a Chemidoc Touch imaging platform (Biorad). Expression levels were then normalized to that of the housekeeping protein β-Actin. Antibodies (H-206; Santa Cruz Biotechnology and ab8227; Abcam, UK). Signal detection produced between a horseradish peroxidase-conjugated secondary antibody (sc-2004; Santa Cruz) and the Chemiluminescent ECL substrate (Biorad) were detected on a Chemidoc Touch imaging platform (Biorad). HIF-1α and protein levels were generated by densitometric analysis with ImageJ and normalized to that of β-Actin.

Quantitative Polymerase Chain Reaction
RNA was extracted using the RNeasy Mini Kit (Qiagen, DE). Hundred nanograms of RNA per sample was reverse transcribed using M-MLV Reverse Transcriptase (Promega, UK) and cDNA was amplified using quantitative polymerase chain reactions (qPCR) in a CFX384 (Biorad). Brilliant III Ultra-Fast SYBR Green QPCR Master Mix (Agilent, USA) was used in conjunction with primers specific to genes of interest. Primer sequences are shown in Supporting Information Table S1. All primers produced a linear relationship between template concentration and Ct value. Reaction efficiencies were confirmed to lie between 90 and 110%. Raw Ct values were converted to transcript copy number by the relative standard curve method of analysis, and expression levels were normalized to that of RPL13A. Following normalization to the housekeeping gene, expression levels were then normalized to that of the untreated control to determine fold change in expression induced by each treatment.

Immunofluorescence Staining
Cultures were fixed in 4% (wt/vol) paraformaldehyde for 15 minutes. HIF-1α and Collagen Type II were then detected using H-206 (Santa Cruz) and ab34712 (Abcam), respectively, overnight, following blocking with (10%) goat serum (Sigma-Aldrich) for 60 minutes and permeabilization in 0.1% (vol/vol) Triton X-100 solution (Sigma Aldrich) for 60 minutes, both at room temperature (RT). Collagen Type X was detected using ab49945 (Abcam) at a 1:250 dilution overnight. Rabbit-derived primary antibodies were detected with biotin (ab6788, Abcam) and Streptavidin (S11223, Thermo Fisher Scientific) both at 1:350 for 60 minutes. Cultures were counterstained with 0.1 µg/ml DAPI for 60 minutes to visualize nuclei and fluorescence was imaged on an Axiovert200M microscope (Zeiss, DE). The images in Supporting Information Figure S1 confirm that signal was due to each primary antibody and not background fluorescence or nonspecific binding of the secondary antibody.

Alcian Blue Staining
Cultures fixed in 4% paraformaldehyde were stained with 1% Alcian blue solution, pH 1.0 (Sigma-Aldrich) prepared in 0.1N HCl. Hematoxylin (Vector Laboratories, UK) was used to visualize cell nuclei and staining was imaged on an Axiovert200M microscope (Zeiss).

Glycosaminoglycan Quantification
At day 21 of chondrogenesis, cultures were washed in phosphate buffered saline and frozen at −80°C before their digestion in 400 µg/ml Papain buffer (Sigma-Aldrich) supplemented with 0.2M Sodium Phosphate + 5 mM Ethylenediaminetetra-acetic acid + 5 mM L-Cysteine (all Sigma-Aldrich) at 65°C for 18 hours. GAGs were quantified from Papain-digested lysates using a Blyscan GAG assay kit (Biocolor, UK) in which GAGs were dyed with 1,9-dimethyl-methylene blue and subsequently dissociated with Propan-1-ol solution before quantification on an absorbance spectrophotometer at 640 nm. Values were normalized to levels of dsDNA, which were quantified using the PicoGreen assay.

Immunofluorescence Quantification
Immunofluorescence images were captured using identical gain, exposure, and offset for all conditions in each experiment. These were determined with positive controls that expressed the antigen of interest, and negative controls in which the primary antibody was omitted (Supporting Information Fig. S1). The same threshold fluorescence intensity for images of all conditions within an experiment was set, below which the signal produced was negated as background. The signal produced above the threshold was regarded as bona fide protein detection and was used to create a binary representation of each image. The percentage of immunofluorescence staining present within a specified area was then determined.

Statistical Analysis
All statistical analyses were performed in Prism7 (GraphPad, USA) with the Mann-Whitney test used to compare two conditions and Kruskal-Wallis with Dunn’s Correction for multiple condition comparisons. Nonparametric tests were used as we were unable to demonstrate normality in all datasets. *marks all differences that were statistically significant (p < .05).

RESULTS
Hypoxia Promotes HIF Stabilization and a More Articular Cartilage-Like Cell Phenotype
It is well established that hBM-MSCs can be chondrogenically differentiated with transforming growth factor β1 (TGF-β1) ligands. Therefore, we first aimed to determine if chondrogenesis could be further enhanced by culture under hypoxic conditions, as previously reported [11]. Hypoxia increased expression of a selection of known HIF target genes including VEGFA, EGLN, and PGK1 (all p = .0286) [27–29] compared with that in hBM-MSC cultured under normoxic conditions (Fig. 2A). These observations were in line with previous studies which have similarly shown a rapid (24 hours) upregulation of HIF and HIF-mediated transcription in response to...
hypoxia under chondrogenic conditions [11]. However, 5%O₂ did not significantly affect expression of SOX9 (Fig. 2A, 2B; \( p = .1 \)), the master transcriptional regulator of chondrogenesis [30], after either 1 or 14 days in culture.

At day 14, we observed upregulation of expression of the gene for the articular cartilage ECM component Collagen Type II (\( \text{COL2A1}, p = .0002 \)), and downregulation of the hypertrophic marker Collagen Type X [31] (\( \text{COL10A1}, p = .0006 \)) under hypoxia under chondrogenic conditions [11]. However, 5%O₂ did not significantly affect expression of SOX9 (Fig. 2A, 2B; \( p = .1 \)), the master transcriptional regulator of chondrogenesis [30], after either 1 or 14 days in culture.
hypoxic conditions compared with that at normoxia (Fig. 2B). 

**COL2A1** and **COL10A1** are targets of transcription factors **SOX9** and **RUNX2**, respectively, and are known to be regulated as the chondrogenic differentiation of MSC proceeds [11]. Culture for 21 days under hypoxic conditions did not affect cell viability or proliferation (Fig. 2C). However, as expected, we did observe increased HIF-1α nuclear localization (*p* < .0001) in hypoxic compared with normoxic cultures (Fig. 2D–2H). Hypoxia also increased Alcian blue staining of GAGs (Fig. 2I, 2J), but did not affect the immuno-detection of Collagen Type II (protein) (Fig. 2K, 2L). Nevertheless, we did detect a decrease in staining for Collagen Type X (Fig. 2M, 2N), consistent with hypoxia’s inhibitory role to chondrocyte hypertrophy [17].

Together, these observations confirmed that culture under hypoxic conditions in the presence of TGF-β1 promoted an articular chondrocyte-like phenotype that was conducive for articular cartilage ECM rather than hypertrophic cartilage formation. This effect appeared to not require a corresponding upregulation of **SOX9**, but instead correlated with increased immunostaining for HIF-1α, upregulation of select HIF target genes **VEGFA**, **EGLN**, and **PGK1**, and increased HIF-1α nuclear localization.

**CoCl2**, **DFX**, and **DMOG** Induce HIF-1α Localization, but Only **DMOG** Strongly Upregulates HIF Targets **VEGFA**, **PGK1**, and **ELGN**

Having determined that hypoxia promoted HIF-1α stabilization and expression of **VEGFA**, **EGLN**, and **PGK1**, we next aimed to determine if inhibitors of the hydroxylases **PHD2** and **FIH** would have a similar effect on hBM-MSC cultured under normoxic conditions. We first determined appropriate doses for the hydroxylase inhibitors **DMOG**, **DFX**, and **CoCl2** by confirming that concentrations of each used extensively in the literature [22, 24, 32–34] were nontoxic to hBM-MSC over 21 days of chondrogenic differentiation (Supporting Information Figs. S2, S3). Next, we confirmed that each could stabilize HIF by carrying out Western blots for HIF-1α in whole-cell lysates after 24 hours, as HIF is known to be rapidly induced in response to PHD2/FIH inhibition [22]. Levels of HIF-1α protein were significantly increased in cells cultured under hypoxic conditions (*p* = .0286); however, despite trends for increased levels of HIF-1α after treatment with HIF stabilizing compounds, we failed to detect statistically significant differences (*p* = .314) compared with controls (Fig. 3A, 3B). Nonetheless, nuclear localization of HIF-1α was enhanced compared with controls (*p* ≤ .0001) in response to treatment with all three compounds (Fig. 3C–3K).

We then examined the effects of the hydroxylase inhibitors on HIF target gene expression. **DMOG** significantly and consistently upregulated expression of **VEGFA** (*p* = day 1: .0073, day 7: .0470, day 21: .0005), **PGK1** (*p* = day 1: .0073, day 7: .0013, day 14: .0013, day 21: .0031), and **EGLN** (*p* = day 1: .0108, day 7: .0332, day 14: .0470, day 21: .0005) (Fig. 3L–3N). However, the effects of **CoCl2** and **DFX** were more subtle, and we only observed upregulation of **PGK1** expression at day 14 (*p* = .0391) and **EGLN** at day 21 (*p* = .0396) in response to **DFX**. These observations show that while **CoCl2**, **DFX**, and **DMOG** all affect HIF-1α stabilization, only **DMOG** strongly upregulated expression of a selection of HIF target genes. This suggests that **DMOG** more potently enhanced HIF activity compared with **DFX** or **CoCl2**.

**DMOG** Stimulates hBM-MSC to Adopt an Articular Chondrocyte-Like Transcriptional Profile

As all HIF mimetics stabilized HIF-1α and **DMOG** also upregulated expression of HIF target genes, we next investigated the effect of these compounds on chondrogenic gene expression. **DMOG** treatment upregulated **SOX9** gene expression after 7 (*p* = .0159) and 21 (*p* = .0332) days in culture (Fig. 4A), while **RUNX2**, a key regulator of osteogenesis [35], was unaffected under all conditions (Fig. 4B). This resulted in a **DMOG**-mediated increase in the **SOX9** to **RUNX2** expression ratio throughout differentiation (Fig. 4C; *p* = day 7: .0192, day 14: .0398, day 21: .0159). All inhibitors upregulated expression of **COL2A1** (Fig. 4D; *p* = **CoCl2**: .0280, **DFX**: .0180, **DMOG**: .0008) with **DMOG** significantly downregulating **COL10A1** (Fig. 4E; *p* = .0037) leading to an increased **COL2A1/COL10A1** mRNA ratio due to **DFX** and **DMOG** (Fig. 4F; *p* = **DFX**: .0259, **DMOG**: <.0001). **ACAN**, which encodes the gene for Aggrecan, the most abundant proteoglycan in cartilage [36], was not upregulated by any treatment (Fig. 4G); and **MMP13**, whose product contributes to an osteoarthritic chondrocyte phenotype [37], was similarly unaffected (Fig. 4H). The articular cartilage phenotype is marked by appropriate post-translational modifications of secreted collagen by enzymes encoded by **P4HA1** and **LOX** [14, 15]. **DMOG** strongly upregulated both **P4HA1** (Fig. 4I; *p* = .0039) and **LOX** (Fig. 4J; *p* = .0027) expression, while **DFX** only upregulated **LOX** (*p* = .0056) and **CoCl2** had no significant effects. Taken together, these observations demonstrate that **DMOG** upregulated transcriptional regulators of chondrogenesis and genes involved in cartilage ECM formation, while the effects of **CoCl2** and **DFX** were more limited.

**DMOG** Inhibits Incorporation of Collagen Type II, Type X, and GAGs into the Cell-Secreted ECM

As treatment with **DMOG** regulated the expression of genes associated with a chondrocyte phenotype, we next asked if this influenced cartilage-like matrix formation. In line with changes in gene expression, hBM-MSC treated with **DMOG** for 21 days showed little to no staining for Collagen Type X compared with controls (Fig. 5A, 5D). We observed a similar effect in both **DFX**- and **CoCl2**-treated cultures (Fig. 5B, 5C). However, while **CoCl2**- and **DFX**-treated cultures showed similar levels of staining for Collagen Type II as controls (Fig. 5E–5G), **DMOG**-treated cultures showed only sparse staining (Fig. 5H). This was confirmed by quantification of Collagen Type II immunofluorescence both without (*p* = .0286) and with normalization to cell number which indicated reduced Collagen Type II production per cell (Fig. 5M; *p* = .0286). Alcian blue staining confirmed these observations as **DMOG**-treated cultures showed fewer GAG-positive areas than the other groups, although quantitative differences in staining on a per cell basis were not significant (Fig. 5I–5L, 5N). Overall, **DMOG** appeared to reduce the total amount of cartilage-like ECM that cells formed in their immediate extracellular space.

**HIF-1α Mediates DMOG’s Induction of an Articular Chondrocyte Transcriptional Profile**

As **DMOG** mediated antithetical effects in terms of chondrogenic transcriptional profile and ECM formation, we next aimed to study its mechanism of action. To accomplish this, we supplemented **CoCl2**/**DFX**/**DMOG**-containing CDM with
Acriflavine (ACF), an inhibitor of HIF-1α and HIF-1β binding [38]. ACF abolished the DMOG-induced upregulation of established HIF targets, but did not affect total cell number during chondrogenesis (Supporting Information Fig. S4A, S4B). Staining for Collagen Type II in DMOG-treated cultures supplemented with ACF remained sparse (Fig. 6A–6C), but quantitative image analyses showed staining on a per cell basis was no different from controls, while cultures treated with DMOG alone were significantly lower (Fig. 6D; p = .0076). This suggests that the inhibitory role of DMOG on Collagen Type II matrix formation may be partly mediated through HIF-1α activity.

We next asked if DMOG's stimulation of the chondrogenic transcription profile in hBM-MSC was also mediated through HIF-1α. ACF abrogated DMOG-mediated changes in expression of HIF targets, VEGFA (Fig. 6E; p = -ACF: .0132, +ACF: .0772) and EGLN (Fig. 6F; p = -ACF: .0073, +ACF: 0.1232), COL2A1 (Fig. 6H; p = -ACF: .0286, +ACF: >.999), COL10A1 (Fig. 6I; p = -ACF: .002, +ACF: >.3277), the COL2A1/COL10A1 ratio (Fig. 6J; p = -ACF: .0031, +ACF: >05998), and showed a...
similar trend for SOX9 expression (Fig. 6G; p = -ACF: .0772, +ACF: .5348) Interestingly, despite a lack of upregulation of SOX9 under hypoxic conditions, we observed a negative effect of hypoxia on SOX9 expression in the presence of ACF (Fig. 6G; p = .0286). This is consistent with the observation that ACF reduced the ratio of COL2A1/COL10A1 under hypoxic conditions (Fig. 6I; p = .0286) and suggests that hypoxia, via HIF-1α, does indeed regulate basal levels of chondrogenic targets genes, such as SOX9. Overall, these data suggest that HIF-1α mediated DMOG's effect on the transcriptional profile of chondrogenically induced hBM-MSC. Moreover, ACF appeared to have a larger effect on DMOG-mediated transcription than that induced by either CoCl2 or DFX (Supporting Information Fig. S4C–S4J).

Late DMOG Treatment Enhances Chondrogenesis

As DMOG upregulated chondrogenic transcripts but continuous treatment led to reduced staining for cartilage-like matrix, we next asked if altering either the length/timing of treatment would influence ECM formation. Therefore, we next treated hBM-MSC with DMOG, DFX, and CoCl2 either continuously (as before) or during late (days 14–21) time periods and analyzed mRNA and protein expression of ECM markers after 21 days. Late DMOG treatment did not negatively affect the secretion of Collagen Type II compared with controls (p = .282), as we observed with continuous DMOG treatment (p = .0188). This contrasted with treatment with either DFX or CoCl2, where both continuous and late treatment had no effect on Collagen Type II secretion (p ≥ .9999 for both, Fig. 7A–7H). At the gene expression level, like continuous treatment (p = .0023), late exposure to DMOG induced significant upregulation of SOX9 (Fig. 7I; p = .0168). Late DMOG also upregulated expression of P4HA1 (Fig. 7I; p = .0286), and HIF targets VEGFA (p = .0358, Fig. 7K) and EGLN (p = .0208, Fig. 7L) as with continuous DMOG treatment (p = P4HA1: .0313, VEGFA: .0118, EGLN: .0088). In contrast, neither continuous nor late CoCl2 and DFX treatment significantly affected the expression of these genes, with the exception of continuous DFX treatment on SOX9 (p = .0286; Fig. 7I) and P4HA1 (p = .0286; Fig. 7I). Taken together, late treatment with DMOG induced a similar expression profile to continuous treatment, but without negatively impacting the formation of cartilage-like ECM.

DISCUSSION

Hypoxic conditions are known to favor articular cartilage development. The pro-chondrogenic effects of hypoxia are thought to be mediated primarily through HIF-1α via the formation of a transcriptionally-active complex at target genes [7, 12]. Therefore, we and others hypothesized that compounds that increase HIF-1α availability would promote HIF-mediated chondrogenesis. Previous studies have examined the effect of CoCl2 [12], DFX [39], and DMOG [21, 40] in this context. While such studies have cemented the role of HIF-1α in chondrogenesis, to our knowledge no study has yet examined their comparative effects during cartilage formation or the chondrogenic differentiation of precursors. As the inhibitors have differential mechanisms of action, comparatively studying their effects may have important implications for HIF biology and cartilage regenerative medicine. Indeed, instead

Figure 4. DMOG induces a chondrogenic transcriptional profile and inhibits markers of osteoblastic and hypertrophic differentiation but also reduces the formation of a cartilage-like ECM. (A–J): Gene expression of SOX9 (A; n = 4), RUNX2 (B; n = 4) and SOX9/RUNX2 (C; n = 4), COL2A1 (D; n = 7), COL10A1 (E; n = 7), COL2A1/COL10A1 (F; n = 7), ACAN (G; n = 4), MMP13 (H; n = 7), P4HA1 (I; n = 4), and LOX (J; n = 7) throughout chondrogenesis due to treatment with CoCl2, DFX, DMOG, and 5%O2. Values are fold change compared with the no-treatment control represented by the horizontal dotted line. Solid colored lines are the mean for each condition. *p < .05 compared with 20%O2 at the same time point. Abbreviations: CoCl2, cobalt chloride; DFX, desferrioxamine, DMOG, dimethyloxalylglycine.
of utilizing physiological hypoxia for regenerative medicine, stabilizing the HIF complex under normoxic conditions would remove the complex logistics required for spatial organization of oxygen. This may be particularly valuable in engineering constructs for the repair of full osteochondral defects due to the contrasting oxygen requirements of avascular cartilage and vascularized bone \[6\]. HIF mimetics could also potentially avoid the undesirable HIF-independent effects of hypoxia such as the unfolded protein response and associated cell stress \[41\], and could preclude the development of a tolerance to the reduced oxygen levels \[42, 43\].

In our control conditions, we defined hypoxia as 5%O\(_2\) to balance its well-described pro-chondrogenic effects against its negative impacts on cell viability \[44\]. As expected, after 24 hours in culture under hypoxic conditions, we detected upregulation of HIF target genes, as others have described \[19, 45\], as well as increased expression of SOX9 target \(COL2A1\) and downregulation \(COL10A1\) (day 14). We also detected an increase in staining for GAGs and reduced Collagen Type X protein formation. Surprisingly, upregulation of SOX9 was not maintained throughout the 21-day differentiation. This is in keeping with previous reports that continued upregulation of SOX9 expression in mouse MSC under hypoxic conditions does not correlate with upregulation of its target genes \[11\]. We also observed that SOX9 expression was downregulated in the presence of ACF, perhaps suggesting that hBM-MSC cultures do rely on HIF for physiological hypoxia’s downstream effects. Indeed, cells may develop a tolerance to hypoxia following the initial induction \[43\], and during long-term culture, hypoxia may act to maintain basal levels of expression of chondrogenic genes.

One of our most striking observations was the ability of DMOG, via HIF-1\(\alpha\), to induce hBM-MSC to upregulate expression of HIF target genes and chondrogenic transcripts, and downregulate mRNA encoding hypertrophic chondrocyte markers such as Collagen Type X. In comparison, neither

Figure 5. DMOG reduces the formation of a cartilage-like ECM. (A–H): Collagen Type X (A–D) and II (E–H) immunofluorescence staining at day 21 of chondrogenesis (n = 3). Scale bar = 400 µm. Brightness and contrast were adjusted to an equal degree between all conditions. (I–L): Alcian blue staining for GAGs with hematoxylin counterstain at day 21 of chondrogenesis (n = 3). Scale bar = 400 µm. (M, N): Quantification of Collagen Type II immunofluorescence (M) and glycosaminoglycans (N) at day 21 of chondrogenesis (n = 4) without and with normalization to DAPI-immunofluorescence/double-stranded DNA. Values are fold change compared with the no-treatment control represented by the horizontal dotted line. Solid colored lines represent means for each condition. *p < .05 compared with 20%O\(_2\). Abbreviations: CoCl\(_2\), cobalt chloride; DFX, desferrioxamine, DMOG, dimethyloxalylglycine; GAGs, glycosaminoglycans.
CoCl₂ nor DFX stimulated similar changes, despite their ability to promote HIF-1α nuclear localization. The stability and nuclear localization of HIF-1α is controlled by PHD2, whereas HIF-1α co-factor binding is controlled by FIH; DMOG has been shown to inhibit both hydroxylases [22]. This is unlike the effect of iron chelators which target PHD2, but do not inhibit FIH as potently [24]. Others have shown that FIH requires higher levels of 2-OG than PHD2 to achieve the same levels of enzymatic activity [46], which may suggest an increased sensitivity of FIH than PHD2 to inhibition by 2-OG analogs. HIF-1α activity in hBM-MSC may also be more dependent on FIH inhibition, rather than PHD2, as high levels of HIF-1α mRNA have been observed in these cells [42]. Indeed, high levels of HIF-1α transcription might compensate for decreases in HIF-1α stability due to PHD2-mediated hydroxylation. Taken together, these observations suggest that regulation of HIF-mediated transcription that is conducive for hBM-MSC articular chondrogenesis is dependant more on 2-OG-mediated mechanisms than those controlled by intracellular Fe^{2+} levels. Additionally, previous studies which demonstrate the dependence of FIH on 2-OG availability and the ability of DMOG to inhibit both PHD2 and FIH, suggest that DMOG’s potent effect here may be via inhibition of both hydroxylases, whereas CoCl₂ and DFX may inhibit PHD2 only.

Figure 6. Inhibition of HIF-1α reduces the DMOG-mediated upregulation of a chondrogenic transcriptional profile. (A–C): Collagen Type II immunofluorescence staining at day 14 of chondrogenesis. Scale bar = 400 μm (n = 4). Brightness and contrast were adjusted to an equal degree between all conditions. (D): Quantification of Collagen Type II immunofluorescence at day 14 of chondrogenic induction, normalized to equivalent DAPI-immunofluorescence (n = 4). Values are fold change compared with the no-treatment control represented by the horizontal dotted line. Orange lines represent means for each condition. *p < .05 compared with 20%O₂. (E–J): Gene expression of VEGFA (E) and EGLN (F), SOX9 (G), COL2A1 (H), COL10A1 (I), and COL2A1/COL10A1 (J) at day 14 of chondrogenesis (n = 4) after treatment with DMOG, 5%O₂, DMOG + Acriflavine, or 5%O₂ + Acriflavine. Values are fold change compared with the no-treatment condition represented by the horizontal dotted line. Solid colored lines represent means for each condition. *p < .05 when compared with 20%O₂, and *p < .05 between +/-ACF conditions within 20%O₂ + DMOG or 5%O₂ groups. Abbreviations: ACF, Acriflavine; DMOG, dimethylxoyalglycine.
The ability of DMOG to induce an expression profile that is conducive for articular chondrogenesis, suggests its advantage over CoCl₂ and DFX for use in cartilage-regenerative therapies. However, despite inducing expression of COL2A1 and genes involved in post-translational modifications of collagen, DMOG had a negative effect on cartilage-like ECM production. We showed that this was partly mediated via HIF-1α; however, other mechanisms are likely involved as we were unable to completely rescue cartilage-like ECM formation with Acriflavine. DMOG has been shown to reduce the activity of prolyl-4-hydroxylase, which is required for correct folding and polymerization of collagen fibrils [21]. Correspondingly, both FIH and collagen prolyl hydroxylase (CP4HA1) have similar affinities for 2-OG, as they have similar $K_m$ values for this co-factor [47]. Therefore, FIH and P4HA1 are likely equally sensitive to DMOG. This suggests that DMOG-mediated upregulation of HIF target genes via FIH inhibition might be accompanied by a similarly potent inhibition of collagen processing and incorporation into the ECM. Treatment with DMOG for the final 7 days of induction restored the reduced levels of Collagen Type II while upregulating expression of HIF target and chondrogenic genes to similar levels we observed in response to continuous treatment. This response could have been mediated by a lack of continuous inhibition of the collagen prolyl hydroxylase. Taken together, late DMOG treatment, which can stimulate the formation of appropriate ECM, and

![Figure 7](https://www.StemCells.com)

**Figure 7.** Late DMOG treatment does not inhibit the formation of a Collagen Type II-rich ECM but does induce a chondrogenic expression profile. (A–G): Collagen Type II immunofluorescence staining at day 21 of chondrogenesis after continuous (days 1–21) and late (days 14–21) CoCl₂, DFX and DMOG treatment ($n = 4$). Scale bar = 400 μm. Representative images from 4 independent repeats shown. Brightness and contrast were adjusted for all channels to an equal degree between all conditions. (H): Quantification of Collagen Type II immunofluorescence at day 21 of chondrogenic induction, normalized to equivalent DAPI-immunofluorescence ($n = 4$). Values are fold change compared with the no-treatment control represented by the horizontal dotted line. The horizontal, colored lines represent means for each condition. *, $p < .05$ compared with 20%O₂. (I–L): Gene expression of SOX9 (I), P4HA1 (J), VEGFA (K), and EGLN (L) after continuous (days 1–21) and late (days 14–21) CoCl₂, DFX and DMOG treatment ($n = 4$). Values are normalized to the housekeeping gene $RPL13A$ and are fold change compared with the no-treatment control, represented by the horizontal dotted line. The horizontal colored lines represent means for each condition. *, $p < .05$ when compared with 20%O₂. Abbreviations: CoCl₂, cobalt chloride; DFX, desferrioxamine, DMOG, dimethylloxalylglycine.
induce mRNA expression of genes similarly to continuous treatment, may be a valuable strategy for cartilage regenerative medicine.

**CONCLUSION**

Hydroxylase inhibitors are potentially valuable in cartilage tissue engineering strategies as they can mimic many of the effects of hypoxia, providing important environmental cues to progenitors, but without many of its potential drawbacks. Here, we show that CoCl$_2$, DFX, and DMOG treatment all induced HIF-1α stabilization. However, unlike CoCl$_2$ and DFX, DMOG treatment strongly regulated HIF targets, and promoted chondrocyte-specific gene expression. This suggests that in hBM-MSC undergoing chondrogenic differentiation, HIF-mediated changes in gene expression may rely more on mechanisms that utilize 2-OG than those that rely on Fe$^{2+}$. Our observations also suggest a role for DMOG in cartilage tissue engineering strategies. For example, scaffolds that spatially and/or temporally control the release of DMOG could target the articular cartilage to aid in the repair of focal defects. However, the maintenance of cartilage ECM in later treatment-only conditions suggests the use of this 2-OG analog would need to be optimized with regard to dosage/treatment time. Alternatively, knowledge that DMOG inhibits both FIH and PHD2 may suggest that dual and specific inhibition of these hydroxylases during de novo cartilage formation may result in HIF-mediated transcription that is conducive for articular chondrogenesis.

**REFERENCES**

1. Kreuz PC, Steinwachs MR, Erggelet C et al. Results after microfracture of full-thickness chondral defects in different compartments in the knee. Osteoarthr Cartilage 2006; 14: 1119–1215.
2. Peterson L, Minas T, Brittberg M et al. Two- to 9-year outcome after autologous chondrocyte transplantation of the knee. Clin Orthop Relat Res 2000; 374: 212–234.
3. Wong KL, Lee KB, Tai BC et al. Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: A prospective, randomized controlled clinical trial with 2 years’ follow-up. Arthroscopy 2013; 29: 2020–2028.
4. Tamaddon M, Burrows M, Ferreira SA et al. Monomeric, porous type II collagen scaffolds promote chondrogenic differentiation of human bone marrow mesenchymal stem cells in vitro. Sci Rep 2017; 7: 43519.
5. McCullen SD, Autefage H, Callanan A et al. Anisotropic fibrous scaffolds for articular cartilage regeneration. Tissue Eng Part A 2012; 18(7–8): 2073–2083.
6. Schipani E, Ryan HE, Didrickson S et al. Hypoxia in cartilage: HIF-1α is essential for chondrocyte growth arrest and survival. Genes Dev 2001; 15: 2865–2876.
7. Provot S, Zinyk D, Gunes Y et al. HIF-1α regulates differentiation of limb bud mesenchyme and joint development. J Cell Biol 2007; 177: 451–464.
8. Hewitson KS, Lienard BM, McDonough MA et al. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem 2007; 282: 3293–3301.
9. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90: 4304–4308.
10. Behrens J, von Kries JP, Kuhl M et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996; 382: 638–642.
11. Robins JC, Akeno N, Mukherjee A et al. Hypoxia induces chondrocyte-specific gene expression in mesenchymal cells in association with transcriptional activation of Sox9. Bone 2005; 37: 313–322.
12. Duval E, Bauge C, Andriamanalijaona R et al. Molecular mechanism of hypoxia-induced chondrogenesis and its application in vivo. Cartilage tissue engineering. Biomaterials 2012; 33: 6042–6051.
13. Amarillo R, Viukov SV, Sharir A et al. HIF-1α regulation of Sox9 is necessary to maintain differentiation of hypoxic prechondrogenic cells during early skeletogenesis. Development 2007; 134: 3917–3928.
14. Aro E, Khatri R, Gerard-O’Riley R et al. Hypoxia-inducible factor-1 (HIF-1) but not HIF-2 is essential for hypoxic induction of collagen prolyl 4-hydroxylases in primary new-born mouse epiphyseal growth plate chondrocytes. J Biol Chem 2012; 287: 37134–37144.

**ACKNOWLEDGMENTS**

D.K.T. acknowledges a Ph.D. studentship from Orthopaedic Research UK and was part funded by the Rosetrees Trust. H.W.A. was supported by Cancer Research UK Clinician Scientist Fellowship (C41494/A15448). Support from the National Institute of Health Research Imperial Biomedical Research Centre, and the Imperial College London Healthcare Tissue Bank are also acknowledged. E.G. acknowledges a Research Career Development Fellowship from the Wellcome Trust and a Philip Leverhulme Prize from the Leverhulme Trust. We thank Angela Gates for administrative assistance and Dr. Chris Healy and Susmitha Rao for technical support.

**AUTHOR CONTRIBUTIONS**

D.K.T.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing; D.F. and S.F.: collection and assembly of data, manuscript revision; S.L.: provision of hBM-MSC, manuscript revision; D.I.: conception and design, data analysis and interpretation, manuscript revision; H.W.A.: provision of hBM-MSC, manuscript revision; A.E.G. and G.J.: conception and design, data analysis and interpretation, manuscript revision; E.G.: conception and design, data analysis and interpretation, manuscript writing, final approval of manuscript.

**DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST**

The authors indicated no potential conflicts of interest.
(PHD2) enhances matrix synthesis by human chondrocytes. J Biol Chem 2010;285:20472–20480.

22 Nguyen LK, Cavadas MA, Scholz CC et al. A dynamic model of the hypoxia-inducible factor 1alpha (HIF-1alpha) network. J Cell Sci 2013;126:1454–1463.

23 Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993;82:3610–3615.

24 Tian YM, Yeoh KK, Lee MK et al. Differential sensitivity of hypoxia inducible factor hydroxylation sites to hypoxia and hydroxylase inhibitors. J Biol Chem 2011;286:13041–13051.

25 Bouaziz W, Sigaux J, Modrowski D et al. Interaction of HIF1alpha and beta-catenin inhibits matrix metalloproteinase 13 expression and prevents cartilage damage in mice. Proc Natl Acad Sci USA 2016;113:5453–5458.

26 Lv F-J, Tuan RS, Cheung KMC et al. Concise review: The surface markers and identity of human mesenchymal stem cells. STEM CELLS 2014;32:1408–1419.

27 Lin C, McGough R, Aswad B et al. Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res 2004;22:1175–1181.

28 Metzen E, Stiehl DP, Doerge K et al. Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: Identification of a functional hypoxia-responsive element. Biochem J 2005;387:711–717.

29 Semenza GL, Roth PH, Fang HM et al. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994;269:23757–23763.

30 Akiyama H, Chaboissier MC, Martin JF et al. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 2002;16:2813–2828.

31 Zheng Q, Zhou G, Morello R et al. Type X collagen gene regulation by Runx2 contributes directly to its hypertrophic chondrocyte-specific expression in vivo. J Cell Biol 2003;162:833–842.

32 Woo KJ, Lee TJ, Park JW et al. Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway. Biochem Biophys Res Commun 2006;343:8–14.

33 Befani C, Mylonis I, Gkotinakou IM et al. Cobalt stimulates HIF-1-dependent but inhibits HIF-2-dependent gene expression in liver cancer cells. Int J Biochem Cell Biol 2013;45:2359.

34 Groenman FA, Rutter M, Wang J et al. Effect of chemical stabilizers of hypoxia-inducible factors on early lung development. Am J Physiol Lung Cell Mol Physiol 2007;293:L557–L567.

35 Komori T, Yagi H, Nomura S et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89:755–764.

36 Gleghorn L, Ramesar R, Beighton P et al. A mutation in the variable repeat region of the aggrecan gene (AGC1) causes a form of spondyloepiphyseal dysplasia associated with severe, premature osteoarthritis. Am J Hum Genet 2005;77:484–490.

37 Reboul P, Pelletier JP, Tardif G et al. The new collagenase, collagenase-3, is expressed in chondrocytes but not by synoviocytes. A role in osteoarthritis. J Clin Invest 1996;97:2011–2019.

38 Lee K, Zhang H, Qian DZ et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci USA 2009;106:17910–17915.

39 Niebler S, Angele P, Kujat R et al. Hypoxia-inducible factor 1 is an inducer of transcription factor activating protein 2 epsilon expression during chondrogenic differentiation. Biomed Res Int 2015;2015:380590.

40 Gelse K, Pfander D, Obier S et al. Role of hypoxia-inducible factor 1 alpha in the integrity of articular cartilage in murine knee joints. Arthritis Res Ther 2008;10:R111.

41 Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003;278:29655–29660.

42 Palomaki S, Pietila M, Laitinen S et al. HIF-1alpha is upregulated in human mesenchymal stem cells. STEM CELLS 2013;31:1902–1909.

43 Park IH, Kim KH, Choi HK et al. Constitutive stabilization of hypoxia-inducible factor alpha selectively promotes the self-renewal of mesenchymal progenitors and maintains mesenchymal stromal cells in an undifferentiated state. Exp Mol Med 2013;45:e44.

44 Makris EA, Gomoll AH, Malizos KN et al. Repair and tissue engineering techniques for articular cartilage. Nat Rev Rheumatol 2015;11:21–34.

45 Leijten J, Georgi N, Moreira Teixeira L et al. Metabolic programming of mesenchymal stromal cells by oxygen tension directs chondrogenic cell fate. Proc Natl Acad Sci USA 2014;111:13954–13959.

46 Tarhonskaya H, Hardy AP, Howe EA et al. Kinetic investigations of the role of factor inhibiting hypoxia-inducible factor (FIH) as an oxygen sensor. J Biol Chem 2015;290:19726–19742.

47 Koivunen P, Hirsila M, Gunzler V et al. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 2004;279:9899–9904.